Trading Report: Today, Neurocrine Biosciences Inc. Forecasted to Earn Q4 2016 Earnings of ($0.54) Per Share (NBIX)

Today, Neurocrine Biosciences Inc. Forecasted to Earn Q4 2016 Earnings of ($0.54) Per Share (NBIX)

Neurocrine Biosciences Inc. (NASDAQ:NBIX) – Oppenheimer Holdings issued their Q4 2016 earnings per share estimates for Neurocrine Biosciences in a research report issued to clients and investors on Monday. Oppenheimer Holdings analyst J. Olson anticipates that the brokerage will post earnings of ($0.54) per share for the quarter. Oppenheimer Holdings has a “Market Perform” rating and a $55.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Neurocrine Biosciences’ Q2 2017 earnings at ($0.56) EPS, FY2018 earnings at $0.64 EPS and FY2019 earnings at $0.55 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.14. During the same quarter in the previous year, the company posted ($0.40) earnings per share. The firm’s quarterly revenue was up .0% compared to the same quarter last year.

A number of other analysts have also recently weighed in on the stock. Piper Jaffray Cos. set a $96.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Tuesday, October 11th. Robert W. Baird reaffirmed an “outperform” rating and issued a $66.00 price objective on shares of Neurocrine Biosciences in a report on Tuesday, August 30th. Leerink Swann began coverage on shares of Neurocrine Biosciences in a report on Tuesday, October 4th. They issued an “outperform” rating and a $70.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Neurocrine Biosciences in a report on Friday, August 5th. Finally, Needham & Company LLC began coverage on shares of Neurocrine Biosciences in a report on Tuesday, October 18th. They issued a “buy” rating and a $62.00 price objective on the stock. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. Neurocrine Biosciences currently has a consensus rating of “Buy” and a consensus target price of $66.92.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) opened at 50.31 on Wednesday. The stock’s market cap is $4.37 billion. Neurocrine Biosciences has a one year low of $31.25 and a one year high of $58.46. The firm has a 50 day moving average of $46.84 and a 200 day moving average of $48.11.

In other news, insider Malcolm Lloyd-Smith sold 9,000 shares of the firm’s stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $50.00, for a total transaction of $450,000.00. Following the completion of the transaction, the insider now owns 9,000 shares in the company, valued at approximately $450,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Christopher Flint Obrien sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $52.84, for a total transaction of $1,321,000.00. Following the transaction, the insider now owns 30,044 shares of the company’s stock, valued at approximately $1,587,524.96. The disclosure for this sale can be found here. Insiders own 4.80% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Alps Advisors Inc. boosted its position in shares of Neurocrine Biosciences by 25.2% in the second quarter. Alps Advisors Inc. now owns 121,734 shares of the company’s stock valued at $5,533,000 after buying an additional 24,508 shares during the last quarter. GW&K Investment Management LLC boosted its position in shares of Neurocrine Biosciences by 27.6% in the second quarter. GW&K Investment Management LLC now owns 85,588 shares of the company’s stock valued at $3,890,000 after buying an additional 18,488 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Neurocrine Biosciences by 890.6% in the second quarter. American Century Companies Inc. now owns 821,527 shares of the company’s stock valued at $37,338,000 after buying an additional 738,598 shares during the last quarter. Moody Aldrich Partners LLC boosted its position in shares of Neurocrine Biosciences by 214.8% in the second quarter. Moody Aldrich Partners LLC now owns 30,960 shares of the company’s stock valued at $1,407,000 after buying an additional 21,125 shares during the last quarter. Finally, Shell Asset Management Co. purchased a new position in shares of Neurocrine Biosciences during the second quarter valued at approximately $496,000. Institutional investors own 96.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Related posts

Leave a Comment